Home › Breast Cancer › Texas
Breast Cancer clinical trials in Texas
177 studies for Breast Cancer are looking for participants at sites in Texas.
Cities in Texas
- Houston126 studies
- Dallas54 studies
- San Antonio46 studies
- Austin18 studies
- League City12 studies
- Fort Worth11 studies
- The Woodlands10 studies
- Sugar Land7 studies
- Lubbock6 studies
- Tyler6 studies
- Irving6 studies
- El Paso6 studies
- Abilene5 studies
- Lewisville5 studies
- Killeen4 studies
- McAllen4 studies
- Cypress3 studies
- Baytown3 studies
- Amarillo3 studies
- Allen3 studies
- Denton3 studies
- Arlington3 studies
Study of AVZO-021 in Patients With Advanced Solid Tumors
- Avenzo Therapeutics Recruiting Site, Dallas
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT05867251A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
- Texas Oncology - DFW ( Site 8003), Dallas
- JPS Health Network ( Site 0067), Fort Worth
- Texas Oncology - Gulf Coast ( Site 8006), Houston
- and 3 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07060807An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
- Next Oncology Austin, Austin
- The University of Texas Md Anderson Cancer Center, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07222267IKS014 in Advanced Solid Tumors That Express HER2
- START Dallas - Fort Worth, Fort Worth
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT05872295BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
- The University of Texas Md Anderson Cancer Center, Houston
- Next Oncology Dallas, Irving
- Next Oncology, San Antonio
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT06120283Opioid-Sparing Effects of Nurse-Delivered Hypnosis During Breast Cancer Surgery
- M D Anderson Cancer Center, Houston
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT05766891A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
- Research Site, Dallas
- Research Site, El Paso
- Research Site, Sugar Land
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06103864A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- The University of Texas MD Anderson Cancer Center, Houston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06172478Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy
- M D Anderson Cancer Center, Houston
Recruiting
Ages 30 and older · Women · Updated Sep 25, 2026 · NCT02945579A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Hendrick Medical Center ( Site 0009), Abilene
- Texas Oncology - DFW ( Site 8009), Dallas
- UT Southwestern ( Site 0092), Dallas
- and 7 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06966700A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
- Texas Oncology-Dallas Presbyterian Hospital ( Site 8000), Dallas
- Parkland Health and Hospital System ( Site 0069), Dallas
- UT Southwestern Medical Center ( Site 0050), Dallas
- and 3 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06312176Group-based Comprehensive Lifestyle Program for Women With Metastatic Breast Cancer
- The University of Texas M. D. Anderson Cancer Center, Houston
Recruiting
Ages 18 and older · Women · Updated Sep 25, 2026 · NCT07179809ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
- University of Texas Southwestern Medical Center, Dallas
- Houston Methodist Cancer Center, Houston
- The University of Texas M.D. Anderson Cancer Center, Houston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07007559TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer
- Houston Methodist Hospital, Houston
RecruitingPhase 1
Ages 18 to 80 · All sexes · Updated Sep 24, 2026 · NCT06251544Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
- Houston Methodist Hospital, Houston
Recruiting
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT07214532Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
- El Paso Texas Oncology, El Paso
- Kelsey Seybold Clinic, Houston
- University of Texas, Houston
- and 2 more
RecruitingPhase 3
Ages 18 to 100 · All sexes · Updated Sep 23, 2026 · NCT05827081A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
- NEXT Oncology - Irving, Irving
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT06618287Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
- Clinical Trial Site, Dallas
- Clinical Trial Site, Dallas
- Clinical Trial Site, Denton
- and 3 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT07085767ARTIDIS Nanomechanical Generated Measurements for Early Breast Lesions
- University of Texas Southwestern Medical Center, Dallas
- Baylor College of Medicine, Houston
- MD Anderson Cancer Clinic - Mays Clinic, Houston
Recruiting
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06085833A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- Hendrick Medical Center, Abilene
- World Research Link, Baytown
- Parkland Health and Hospital System, Dallas
- and 10 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07174336A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Texas Oncology - DFW (Sammons CC), Dallas
- Baylor College of Medicine, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07213791A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
- University of Texas MD Anderson Cancer Center, Houston
- Houston Methodist Hospital, Houston
- Oncology Consultants P.A., Houston
- and 1 more
RecruitingPhase 2
Ages 18 and older · Women · Updated Sep 22, 2026 · NCT07287098A Study of LY4257496 in Participants With Cancer (OMNIRAY)
- Texas Oncology - DFW (Sammons CC), Dallas
- MD Anderson Cancer Center, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07114601A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
- Renovatio Clinical - El Paso, El Paso
- JPS Health Network, Fort Worth
- Renovatio Clinical, The Woodlands
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT05894239A Study of JNJ-101684362 (HLD-0117) in Patients With Metastatic Breast Cancer
- South Texas Accelerated Research Therapeutics, LLC (START), San Antonio
RecruitingPhase 1
Ages 18 and older · Women · Updated Sep 21, 2026 · NCT07524855Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
- Baylor College of Medicine, Houston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT07340541Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
- Baylor Medicine, Houston
- MD Anderson Cancer Center, Houston
Recruiting
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT03796559Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
- M D Anderson Cancer Center, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT04038619A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
- Baylor Scott & White Research Institute -Texas Oncology, Dallas
- UT Southwestern Medical Center, Dallas
- South Texas Accelerated Research Therapeutics (START), LLC, San Antonio
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT06827236ATUSA Ultrasound Diagnostic Imaging for Breast Lesions Evaluation (AUDIBLE) - iSono Health
- Cypress Innovative Breast Care Center, Cypress
RecruitingObservational study
Ages 18 to 94 · Women · Updated Sep 17, 2026 · NCT07505797ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
- OneR The Center For Cancer And Blood Disorders (Texas Cancer Care), Arlington
- OneR The Center For Cancer And Blood Disorders (Texas Cancer Care), Burleson
- UT Southwestern Medical Center at Redbird, Dallas
- and 9 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT07173751A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- MD Anderson Cancer Center, Houston
- START Center for Cancer Research, San Antonio
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT07109726A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
- NEXT Dallas, Irving
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT07578571Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- The Methodist Hospital Research Institute, Houston
- The University of Texas MD Anderson Cancer Center, Houston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT06324357The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- New Experimental Therapeutics - NEXT Oncology, Austin
- Texas Oncology, Bedford
- UT Southwest Simmons Cancer Center, Dallas
- and 2 more
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Sep 15, 2026 · NCT04585750A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
- Hendrick Cancer Center, Abilene
- Texas Oncology-Northeast Texas, Allen
- Texas Oncology - DFW, Dallas
- and 9 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT06492616Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer
- M D Anderson Cancer Center, Houston
RecruitingPhase 2
Ages 18 and older · Women · Updated Sep 14, 2026 · NCT04090567BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
- Md Anderson Cancer Center, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT06756932A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- Research Site, Houston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT05123482Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
- Texas Oncology - DFW ( Site 8000), Dallas
- Houston Methodist Hospital ( Site 0022), Houston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 10, 2026 · NCT06797635From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.